MediciNova, Inc. (NASDAQ: MNOV) is a Healthcare company (Biotechnology) with a market capitalization of $69M. The Maz Rating grades it against the other companies in its sector.
MediciNova, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.34, MediciNova, Inc. trades at 75.0x sales and 1.6x book value. Over the last twelve months it generated about $915227 of revenue and a net loss of $11M. It runs a gross margin of 46.8%, an operating margin of -1232.2% and a net margin of -1127.0%. It shows return on equity of -26.5%, return on invested capital of -27.5% and a free cash flow yield of -14.1%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 8.75. Over the past 52 weeks the share price ranged from $1.22 to $3.90, with a beta of 0.61.
MediciNova, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 4 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, MediciNova, Inc. (MNOV) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 35.0% / 30% · Interest income / Revenue 158.4% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 35.0% / 33% · Receivables / Mkt Cap (36m) 0.72% / 49% · Interest income / Revenue 158.4% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 35.0% / 33.33% · Receivables / Mkt Cap (24m) 0.72% / 33.33% · Interest income / Revenue 158.4% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 64.8% / 33.33% · Receivables / Avg Assets (4Q) 0.49% / 33.33% · Interest income / Revenue 158.4% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 64.7% / 33.33% · (Cash+Recv) / Total Assets 66.0% / 33.33% · Interest income / Revenue 158.4% / 5% | Fail |
No. As of September 2026, MediciNova, Inc. (MNOV) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. MediciNova, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 158.4% of each dividend: MediciNova, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.